Clinical outcome
No significant differences were observed between the CPT-FPV and sotrovimab groups regarding emergency department visits within 14 and 28 days, rates of ICU admission, oxygen supplementation, invasive mechanical ventilation, and mortality.Furthermore, the two treatment groups had no notable clinical improvement, deterioration, or stability variations. The clinical outcomes indicated that 46 (67.7%) patients in the CPT-FPV group and 44 (64.7%) patients in the sotrovimab group experienced clinical improvement by day 2, while 63 (92.7%) patients in the CPT-FPV group and 60 (88.2%) patients in the sotrovimab group exhibited clinical improvement by day 5. According to days 5 and 14, all patients had a WHO clinical progression scale (WHO-CPS) score of 2 or lower. On day 5, 85.3% of CPT-FPV patients and 79.4% of sotrovimab patients had a WHO-CPS score of 1, while 76.5% of CPT-FPV patients and 88.2% of sotrovimab patients had a WHO-CPS score of 0 by day 14 (In a 